Bactericidal and Virucidal Efficacies and Safety of Puriton ®.

Bok, So-Hyeon; Kim, Min-Hee; Lee, Soon-Young; Bae, Chun-Sik; Lee, Min-Jae; Kim, Kwang-Ho; Park, Dae-Hun

In 2016, infectious microbes were one of the leading causes of death, especially in developing countries. Puriton® is a mineral mixture consisting of biotite, kaolinite, montmorillonite, serpentine, clinochlore, and vermiculite, and evaluated antimicrobial activity in vitro and safety in vivo. Nine pathogens and opportunistic bacteria, namely Salmonella typhimurium, Escherichia coli, Pseudomonas aeruginosa, Alcaligenes faecalis, Staphylococcus aureus, Enterococcus faecalis, Micrococcus luteus, Mycobacterium smegmatis, and Bacillus subtilis, and the two viruses Zika and Influenza A/Duck/MN/1525/81 were used. A 26-week oral repeated safety study of Puriton® was conducted. Puriton® suppressed the bacterial proliferation, with a minimum proliferative rate of 91.1% in B. subtilis ATCC6633. The virucidal efficacy of Puriton® against Zika virus after 4 h and 18 h of contact time was significant in all groups treated with Puriton®. Twenty-six-week repeated oral administration of Puriton® was considered safe based on physiological results, such as behavior and blood cells/chemistry, and histopathological changes in the brain, heart, kidney, liver, and lung. We concluded that Puriton® exerted bactericidal and virucidal efficacies and was safe for 26-week repeated oral administration.

MICROCOCCUS luteus; MYCOBACTERIUM smegmatis; SALMONELLA typhimurium; ZIKA virus; ENTEROCOCCUS faecalis; ENTEROCOCCUS

Processes, 2020, Vol 8, Issue 11, p1481

2227-9717

Academic Journal

10.3390/pr8111481